Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	28.18B
Revenue (ttm)	5.94B
Net Income (ttm)	1.22B
Shares Out	1.02B
EPS (ttm)	1.20
PE Ratio	23.11
Forward PE	21.18
Dividend	0.36 (1.30%)
Ex-Dividend Date	May 14, 2025

Volume	9,894,337
Average Volume	16,176,505
Open	28.54
Previous Close	28.70
Day's Range	27.68 - 28.54
52-Week Range	20.36 - 29.98
Beta	-0.26
RSI	57.65
Earnings Date	Oct 24, 2025

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine fumarate, injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, duloxetine hydrochloride enteric dissolving capsules, olan...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 5,923
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2024, SHE:002262's revenue was 5.70 billion, an increase of 13.01% compared to the previous year's 5.04 billion. Earnings were 1.14 billion, an increase of 10.28%.